+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Male Infertility Market By Treatment, By Test, By Country, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 73 Pages
  • June 2020
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5129373
The Latin America, Middle East and Africa Male Infertility Market is expected to witness market growth of 8.5% CAGR during the forecast period (2020-2026).

Elements of adult and gender identity can never be realized in infertile individuals due to the loss of pregnancy, childbirth, and lack of family and generational continuity and inclusiveness within their wider community. High levels of clinically relevant symptoms of depression and anxiety, suicidal thoughts, and a heavy conceptualization of grief impact infertile individuals. Mental health and psychosocial problems and resources need to address key factors of depression, such as poverty, sexual abuse, and infertility.

Growing rates of infertility worldwide and the introduction of assisted reproductive technologies (ARTs) are expected to push the demand for male infertility in the coming years. ARTs address a wide variety of infertility therapies that provide remedies for males facing issues such as reduced sperm count, irregular sperm quality, and poor motility. In addition, ARTs deliver a high success rate compared to drugs. The demand for male infertility is expected to see substantial development in the future due to technical developments in the area of assisted reproductive technology.

Tobacco smoke contains approximately 4,000 compounds, like alkaloids, nitrosamines, and inorganic molecules, and some of these are reactive oxygen or nitrogen species. A positive and significant association has been identified between active smoking and sperm DNA fragmentation and also axonemal damage. Smoking is often associated with a decreased sperm count. Smoking is considered to enhance spermatogenesis by increasing the production of norepinephrine, which increases the conversion of testosterone to estrogen causing decreased testosterone levels.

Based on Treatment, the market is segmented into Assisted Reproductive Technology & Varicocele Surgery and Medication. Based on Test, the market is segmented into DNA Fragmentation Technique, Oxidative Stress Analysis, Computer Assisted Semen Analysis, Microscopic Examination, Sperm Agglutination, Sperm Penetration Assay and Other Tests. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Bayer AG, Cadila Healthcare Ltd. (Zydus Cadila), Endo International PLC, Aytu BioScience, Inc., Vitrolife AB, SCSA Diagnostics, Inc., Andrology Solutions Limited, Halotech DNA SL, and Intas Pharmaceutical Ltd.

Scope of the Study

Market Segmentation:

By Treatment
  • Assisted Reproductive Technology & Varicocele Surgery and
  • Medication

By Tests
  • DNA Fragmentation Technique
  • Oxidative Stress Analysis
  • Computer Assisted Semen Analysis
  • Microscopic Examination
  • Sperm Agglutination
  • Sperm Penetration Assay and
  • Other Tests

By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • Sanofi S.A.
  • Bayer AG
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Endo International PLC
  • Aytu BioScience, Inc.
  • Vitrolife AB
  • SCSA Diagnostics, Inc.
  • Andrology Solutions Limited
  • Halotech DNA SL
  • Intas Pharmaceutical Ltd.

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Male Infertility Market, by Treatment
1.4.2 LAMEA Male Infertility Market, by Tests
1.4.3 LAMEA Male Infertility Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Male Infertility Market by Treatment
3.1 LAMEA Assisted Reproductive Technology and Varicocele Surgery Market by Country
3.2 LAMEA Medication Market by Country
Chapter 4. LAMEA Male Infertility Market by Test
4.1 LAMEA DNA Fragmentation Technique Market by Country
4.2 LAMEA Oxidative Stress Analysis Market by Country
4.3 LAMEA Computer Assisted Semen Analysis Market by Country
4.4 LAMEA Microscopic Examination Market by Country
4.5 LAMEA Sperm Agglutination Market by Country
4.6 LAMEA Sperm Penetration Assay Market by Country
4.7 LAMEA Other Test Market by Country
Chapter 5. LAMEA Male Infertility Market by Country
5.1 Brazil Male Infertility Market
5.1.1 Brazil Male Infertility Market by Treatment
5.1.2 Brazil Male Infertility Market by Test
5.2 Argentina Male Infertility Market
5.2.1 Argentina Male Infertility Market by Treatment
5.2.2 Argentina Male Infertility Market by Test
5.3 UAE Male Infertility Market
5.3.1 UAE Male Infertility Market by Treatment
5.3.2 UAE Male Infertility Market by Test
5.4 Saudi Arabia Male Infertility Market
5.4.1 Saudi Arabia Male Infertility Market by Treatment
5.4.2 Saudi Arabia Male Infertility Market by Test
5.5 South Africa Male Infertility Market
5.5.1 South Africa Male Infertility Market by Treatment
5.5.1.1.1 South Africa Male Infertility Market by Test
5.6 Nigeria Male Infertility Market
5.6.1 Nigeria Male Infertility Market by Treatment
5.6.2 Nigeria Male Infertility Market by Test
5.7 Rest of LAMEA Male Infertility Market
5.7.1 Rest of LAMEA Male Infertility Market by Treatment
5.7.2 Rest of LAMEA Male Infertility Market by Test
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bayer AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Cadila Healthcare Ltd. (Zydus Cadila)
6.3.1 Company Overview
6.3.1 Financial Analysis
6.3.2 Regional Analysis
6.3.3 Research & Development Expense
6.4 Endo International PLC
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental Analysis
6.4.4 Research & Development Expense
6.5 Aytu BioScience, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.5.5.2 Partnerships, Collaborations, and Agreements:
6.6 Vitrolife AB
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expenses
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 SCSA Diagnostics, Inc.
6.7.1 Company Overview
6.8 Andrology Solutions Limited
6.8.1 Company Overview
6.9 Halotech DNA SL
6.9.1 Company Overview
6.10 Intas Pharmaceutical Ltd.
6.10.1 Company Overview

Companies Mentioned

  • Sanofi S.A.
  • Bayer AG
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Endo International PLC
  • Aytu BioScience, Inc.
  • Vitrolife AB
  • SCSA Diagnostics, Inc.
  • Andrology Solutions Limited
  • Halotech DNA SL
  • Intas Pharmaceutical Ltd.

Methodology

Loading
LOADING...